TY - JOUR AU - Tallman, M. S. AU - Gilliland, D. G. AU - Rowe, J. M. PY - 2005 DA - 2005// TI - Drug therapy for acute myeloid leukemia JO - Blood VL - 106 UR - https://doi.org/10.1182/blood-2005-01-0178 DO - 10.1182/blood-2005-01-0178 ID - Tallman2005 ER - TY - JOUR AU - Galmarini, C. M. AU - Thomas, X. AU - Calvo, F. AU - Rousselot, P. AU - Rabilloud, M. AU - Jaffari, A. PY - 2002 DA - 2002// TI - In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia JO - Br J Haematol VL - 117 UR - https://doi.org/10.1046/j.1365-2141.2002.03538.x DO - 10.1046/j.1365-2141.2002.03538.x ID - Galmarini2002 ER - TY - JOUR AU - Styczynski, J. PY - 2007 DA - 2007// TI - Drug resistance in childhood acute myeloid leukemia JO - Curr Pharm Biotechnol VL - 8 UR - https://doi.org/10.2174/138920107780487465 DO - 10.2174/138920107780487465 ID - Styczynski2007 ER - TY - JOUR AU - Falk, I. J. AU - Fyrberg, A. AU - Paul, E. AU - Nahi, H. AU - Hermanson, M. AU - Rosenquist, R. PY - 2013 DA - 2013// TI - Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5′-nucleotidase JO - Am J Hematol VL - 88 UR - https://doi.org/10.1002/ajh.23549 DO - 10.1002/ajh.23549 ID - Falk2013 ER - TY - JOUR AU - Mahlknecht, U. AU - Dransfeld, C. L. AU - Bulut, N. AU - Kramer, M. AU - Thiede, C. AU - Ehninger, G. PY - 2009 DA - 2009// TI - SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival JO - Leukemia VL - 23 UR - https://doi.org/10.1038/leu.2009.113 DO - 10.1038/leu.2009.113 ID - Mahlknecht2009 ER - TY - JOUR AU - Mitra, A. K. AU - Crews, K. R. AU - Pounds, S. AU - Cao, X. AU - Feldberg, T. AU - Ghodke, Y. PY - 2011 DA - 2011// TI - Genetic variants in cytosolic 5′-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia JO - J Pharmacol Exp Ther VL - 339 UR - https://doi.org/10.1124/jpet.111.182873 DO - 10.1124/jpet.111.182873 ID - Mitra2011 ER - TY - JOUR AU - Bartel, D. P. PY - 2004 DA - 2004// TI - MicroRNAs: genomics, biogenesis, mechanism, and function JO - Cell VL - 116 UR - https://doi.org/10.1016/S0092-8674(04)00045-5 DO - 10.1016/S0092-8674(04)00045-5 ID - Bartel2004 ER - TY - JOUR AU - Ryan, B. M. AU - Robles, A. I. AU - Harris, C. C. PY - 2010 DA - 2010// TI - Genetic variation in microRNA networks: the implications for cancer research JO - Nat Rev Cancer VL - 10 UR - https://doi.org/10.1038/nrc2867 DO - 10.1038/nrc2867 ID - Ryan2010 ER - TY - JOUR AU - Mishra, P. J. AU - Humeniuk, R. AU - Mishra, P. J. AU - Longo-Sorbello, G. S. AU - Banerjee, D. PY - 2007 DA - 2007// TI - Bertino JR.A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance JO - Proc Natl Acad Sci USA VL - 104 UR - https://doi.org/10.1073/pnas.0706217104 DO - 10.1073/pnas.0706217104 ID - Mishra2007 ER - TY - JOUR AU - Salzman, D. W. PY - 2013 DA - 2013// TI - Weidhaas JB.SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer JO - Pharmacol Ther VL - 137 UR - https://doi.org/10.1016/j.pharmthera.2012.08.016 DO - 10.1016/j.pharmthera.2012.08.016 ID - Salzman2013 ER - TY - JOUR AU - Larrea, C. F. AU - Navarro, A. AU - Tejero, R. AU - Tovar, N. AU - Diaz, T. AU - Cibeira, M. T. PY - 2012 DA - 2012// TI - Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-12-0191 DO - 10.1158/1078-0432.CCR-12-0191 ID - Larrea2012 ER - TY - JOUR AU - Cheson, B. D. AU - Bennett, J. M. AU - Kopecky, K. J. AU - Buchner, T. AU - Willman, C. L. AU - Estey, E. H. PY - 2003 DA - 2003// TI - Revised recommendations of the International Working Group for Diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.04.036 DO - 10.1200/JCO.2003.04.036 ID - Cheson2003 ER - TY - STD TI - National Institute of Cancer. Common terminology criteria for adverse events (CTCAE). NIH Publication; 2009. p. 0-71. ID - ref13 ER - TY - JOUR AU - Emadi, A. AU - Karp, J. E. PY - 2012 DA - 2012// TI - The clinically relevant pharmacogenomic changes in acute myelogenous leukemia JO - Pharmacogenomics VL - 13 UR - https://doi.org/10.2217/pgs.12.102 DO - 10.2217/pgs.12.102 ID - Emadi2012 ER - TY - JOUR AU - Lamba, J. K. PY - 2009 DA - 2009// TI - Genetic factors influencing cytarabine therapy JO - Pharmacogenomics VL - 10 UR - https://doi.org/10.2217/pgs.09.118 DO - 10.2217/pgs.09.118 ID - Lamba2009 ER - TY - JOUR AU - Megias-Vericat, J. E. AU - Montesinos, P. AU - Herrero, M. J. AU - Boso, V. AU - Martinez-Cuadron, D. AU - Poveda, J. L. PY - 2016 DA - 2016// TI - Pharmacogenomics and the treatment of acute myeloid leukemia JO - Pharmacogenomics VL - 17 UR - https://doi.org/10.2217/pgs-2016-0055 DO - 10.2217/pgs-2016-0055 ID - Megias-Vericat2016 ER - TY - JOUR AU - Yuan, X. Q. AU - Zhang, D. Y. AU - Yan, H. AU - Yang, Y. L. AU - Zhu, K. W. AU - Chen, Y. H. PY - 2016 DA - 2016// TI - Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.11143 DO - 10.18632/oncotarget.11143 ID - Yuan2016 ER - TY - JOUR AU - Dumontet, C. AU - Bauchu, E. C. AU - Fabianowska, K. AU - Lepoivre, M. AU - Wyczechowska, D. AU - Bodin, F. PY - 1999 DA - 1999// TI - Common resistance mechanisms to nucleoside analogues in variants of the human erythroleukemic line K562 JO - Adv Exp Med Biol VL - 457 UR - https://doi.org/10.1007/978-1-4615-4811-9_63 DO - 10.1007/978-1-4615-4811-9_63 ID - Dumontet1999 ER - TY - JOUR AU - Hunsucker, S. A. AU - Mitchell, B. S. AU - Spychala, J. PY - 2005 DA - 2005// TI - The 5′-nucleotidases as regulators of nucleotide and drug metabolism JO - Pharmacol Ther VL - 107 UR - https://doi.org/10.1016/j.pharmthera.2005.01.003 DO - 10.1016/j.pharmthera.2005.01.003 ID - Hunsucker2005 ER - TY - JOUR AU - Galmarini, C. M. AU - Cros, E. AU - Thomas, X. AU - Jordheim, L. AU - Dumontet, C. PY - 2005 DA - 2005// TI - The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia JO - Haematologica VL - 90 ID - Galmarini2005 ER - TY - JOUR AU - Galmarini, C. M. PY - 2007 DA - 2007// TI - What does over-expression of cN-II enzyme signify in haematological malignancies? JO - Leuk Res VL - 31 UR - https://doi.org/10.1016/j.leukres.2007.02.006 DO - 10.1016/j.leukres.2007.02.006 ID - Galmarini2007 ER - TY - JOUR AU - Clarke, M. L. AU - Mackey, J. R. AU - Baldwin, S. A. AU - Young, J. D. AU - Cass, C. E. PY - 2002 DA - 2002// TI - The role of membrane transporters in cellular resistance to anticancer nucleoside drugs JO - Cancer Treat Res VL - 112 UR - https://doi.org/10.1007/978-1-4615-1173-1_2 DO - 10.1007/978-1-4615-1173-1_2 ID - Clarke2002 ER - TY - JOUR AU - Reese, N. D. AU - Schiller, G. J. PY - 2013 DA - 2013// TI - High-dose cytarabine (HD araC) in the treatment of leukemias: a review JO - Curr Hematol Malig Rep VL - 8 UR - https://doi.org/10.1007/s11899-013-0156-3 DO - 10.1007/s11899-013-0156-3 ID - Reese2013 ER - TY - JOUR AU - Cai, J. AU - Damaraju, V. L. AU - Groulx, N. AU - Mowles, D. AU - Peng, Y. AU - Robins, M. J. PY - 2008 DA - 2008// TI - Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-07-5528 DO - 10.1158/0008-5472.CAN-07-5528 ID - Cai2008 ER - TY - JOUR AU - Galmarini, C. M. AU - Thomas, X. AU - Calvo, F. AU - Rousselot, P. AU - Jafaari, A. AU - Cros, E. PY - 2002 DA - 2002// TI - Potential mechanisms of resistance to cytarabine in AML patients JO - Leuk Res VL - 26 UR - https://doi.org/10.1016/S0145-2126(01)00184-9 DO - 10.1016/S0145-2126(01)00184-9 ID - Galmarini2002 ER - TY - JOUR AU - Macanas-Pirard, P. AU - Leisewitz, A. AU - Broekhuizen, R. AU - Cautivo, K. AU - Barriga, F. M. AU - Leisewitz, F. PY - 2012 DA - 2012// TI - Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis JO - PLoS ONE VL - 7 UR - https://doi.org/10.1371/journal.pone.0037203 DO - 10.1371/journal.pone.0037203 ID - Macanas-Pirard2012 ER - TY - JOUR AU - Amaki, J. AU - Onizuka, M. AU - Ohmachi, K. AU - Aoyama, Y. AU - Hara, R. AU - Ichiki, A. PY - 2015 DA - 2015// TI - Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy JO - Int J Hematol VL - 101 UR - https://doi.org/10.1007/s12185-015-1766-4 DO - 10.1007/s12185-015-1766-4 ID - Amaki2015 ER - TY - JOUR AU - Wan, H. AU - Zhu, J. AU - Chen, F. AU - Xiao, F. AU - Huang, H. AU - Han, X. PY - 2014 DA - 2014// TI - SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study JO - J Exp Clin Cancer Res VL - 33 UR - https://doi.org/10.1186/s13046-014-0090-9 DO - 10.1186/s13046-014-0090-9 ID - Wan2014 ER - TY - JOUR AU - Kim, J. H. AU - Lee, C. AU - Cheong, H. S. AU - Koh, Y. AU - Ahn, K. S. AU - Kim, H. L. PY - 2016 DA - 2016// TI - SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia JO - Cancer Chemother Pharmacol VL - 78 UR - https://doi.org/10.1007/s00280-016-3103-x DO - 10.1007/s00280-016-3103-x ID - Kim2016 ER - TY - JOUR AU - Kim, K. I. AU - Huh, I. S. AU - Kim, I. W. AU - Park, T. AU - Ahn, K. S. AU - Yoon, S. S. PY - 2013 DA - 2013// TI - Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2012.07.022 DO - 10.1016/j.ejca.2012.07.022 ID - Kim2013 ER - TY - JOUR AU - Shao, J. AU - Zhou, B. AU - Chu, B. AU - Yen, Y. PY - 2006 DA - 2006// TI - Ribonucleotide reductase inhibitors and future drug design JO - Curr Cancer Drug Targets VL - 6 UR - https://doi.org/10.2174/156800906777723949 DO - 10.2174/156800906777723949 ID - Shao2006 ER - TY - JOUR AU - Liliemark, J. O. AU - Plunkett, W. PY - 1986 DA - 1986// TI - Regulation of 1-beta-d-arabinofuranosylcytosine 5′-triphosphate accumulation in human leukemia cells by deoxycytidine 5′-triphosphate JO - Cancer Res VL - 46 ID - Liliemark1986 ER - TY - JOUR AU - Chabner, B. A. AU - Hande, K. R. AU - Drake, J. C. PY - 1979 DA - 1979// TI - Ara-C metabolism: implications for drug resistance and drug interactions JO - Bull Cancer VL - 66 ID - Chabner1979 ER - TY - JOUR AU - Chiba, P. AU - Tihan, T. AU - Szekeres, T. AU - Salamon, J. AU - Kraupp, M. AU - Eher, R. PY - 1990 DA - 1990// TI - Concordant changes of pyrimidine metabolism in blasts of two cases of acute myeloid leukemia after repeated treatment with ara-C in vivo JO - Leukemia VL - 4 ID - Chiba1990 ER - TY - JOUR AU - Gandhi, V. AU - Estey, E. AU - Du, M. AU - Nowak, B. AU - Keating, M. J. AU - Plunkett, W. PY - 1995 DA - 1995// TI - Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia JO - Clin Cancer Res VL - 1 ID - Gandhi1995 ER - TY - JOUR AU - Gandhi, V. AU - Estey, E. AU - Du, M. AU - Keating, M. J. AU - Plunkett, W. PY - 1997 DA - 1997// TI - Minimum dose of fludarabine for the maximal modulation of 1-beta-d-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy JO - Clin Cancer Res VL - 3 ID - Gandhi1997 ER - TY - JOUR AU - Cao, X. AU - Mitra, A. K. AU - Pounds, S. AU - Crews, K. R. AU - Gandhi, V. AU - Plunkett, W. PY - 2013 DA - 2013// TI - RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients JO - Pharmacogenomics VL - 14 UR - https://doi.org/10.2217/pgs.13.131 DO - 10.2217/pgs.13.131 ID - Cao2013 ER - TY - JOUR AU - Rubnitz, J. E. AU - Crews, K. R. AU - Pounds, S. AU - Yang, S. AU - Campana, D. AU - Gandhi, V. V. PY - 2009 DA - 2009// TI - Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial JO - Leukemia VL - 23 UR - https://doi.org/10.1038/leu.2009.30 DO - 10.1038/leu.2009.30 ID - Rubnitz2009 ER - TY - JOUR AU - Leist, T. P. AU - Weissert, R. PY - 2011 DA - 2011// TI - Cladribine: mode of action and implications for treatment of multiple sclerosis JO - Clin Neuropharmacol VL - 34 UR - https://doi.org/10.1097/WNF.0b013e318204cd90 DO - 10.1097/WNF.0b013e318204cd90 ID - Leist2011 ER - TY - JOUR AU - Capizzi, R. L. AU - White, J. C. AU - Powell, B. L. AU - Perrino, F. PY - 1991 DA - 1991// TI - Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine JO - Semin Hematol VL - 28 ID - Capizzi1991 ER - TY - JOUR AU - Fridland, A. AU - Verhoef, V. PY - 1987 DA - 1987// TI - Mechanism for ara-CTP catabolism in human leukemic cells and effect of deaminase inhibitors on this process JO - Semin Oncol VL - 14 ID - Fridland1987 ER - TY - JOUR AU - Wang, H. AU - Jin, G. AU - Wang, H. AU - Liu, G. AU - Qian, J. AU - Jin, L. PY - 2009 DA - 2009// TI - Genetic susceptibility of lung cancer associated with common variants in the 3′ untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export JO - Cancer VL - 115 UR - https://doi.org/10.1002/cncr.24042 DO - 10.1002/cncr.24042 ID - Wang2009 ER - TY - JOUR AU - Wojnowski, L. AU - Kulle, B. AU - Schirmer, M. AU - Schluter, G. AU - Schmidt, A. AU - Rosenberger, A. PY - 2005 DA - 2005// TI - NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity JO - Circulation VL - 112 UR - https://doi.org/10.1161/CIRCULATIONAHA.105.576850 DO - 10.1161/CIRCULATIONAHA.105.576850 ID - Wojnowski2005 ER - TY - JOUR AU - Megías, J. E. AU - Montesinos, P. AU - Herrero, M. J. AU - Moscardó, F. AU - Boso, V. AU - Martínez-Cuadrón, D. AU - Rojas, L. AU - Rodriguez-Veiga, R. AU - Boluda, B. AU - Martinez, J. AU - Sanz, J. AU - López, F. AU - Cano, I. AU - Lancharro, A. AU - Cervera, J. AU - Hervás, D. AU - Poveda, J. L. AU - Aliño, S. F. AU - Sanz, M. Á. PY - 2015 DA - 2015// TI - Impact of transporter genes polymorphisms in standard induction of acute myeloid leukemia JO - Am Soc Hematol VL - 126 ID - Megías2015 ER - TY - JOUR AU - Lal, S. AU - Sandanaraj, E. AU - Wong, Z. W. AU - Ang, P. C. AU - Wong, N. S. AU - Lee, E. J. PY - 2008 DA - 2008// TI - CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients JO - Cancer Sci VL - 99 UR - https://doi.org/10.1111/j.1349-7006.2008.00744.x DO - 10.1111/j.1349-7006.2008.00744.x ID - Lal2008 ER - TY - JOUR AU - Blanco, J. G. AU - Sun, C. L. AU - Landier, W. AU - Chen, L. AU - Esparza-Duran, D. AU - Leisenring, W. PY - 2012 DA - 2012// TI - Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the Children’s Oncology Group JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.34.8987 DO - 10.1200/JCO.2011.34.8987 ID - Blanco2012 ER - TY - JOUR AU - Gonzalez-Covarrubias, V. AU - Zhang, J. AU - Kalabus, J. L. AU - Relling, M. V. AU - Blanco, J. G. PY - 2009 DA - 2009// TI - Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors JO - Drug Metab Dispos VL - 37 UR - https://doi.org/10.1124/dmd.108.024547 DO - 10.1124/dmd.108.024547 ID - Gonzalez-Covarrubias2009 ER - TY - JOUR AU - Kalabus, J. L. AU - Cheng, Q. AU - Blanco, J. G. PY - 2012 DA - 2012// TI - MicroRNAs differentially regulate carbonyl reductase 1 (CBR1) gene expression dependent on the allele status of the common polymorphic variant rs9024 JO - PLoS ONE VL - 7 UR - https://doi.org/10.1371/journal.pone.0048622 DO - 10.1371/journal.pone.0048622 ID - Kalabus2012 ER - TY - JOUR AU - Flach, J. AU - Dicker, F. AU - Schnittger, S. AU - Schindela, S. AU - Kohlmann, A. AU - Haferlach, T. PY - 2011 DA - 2011// TI - An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling JO - Leukemia VL - 25 UR - https://doi.org/10.1038/leu.2010.304 DO - 10.1038/leu.2010.304 ID - Flach2011 ER - TY - JOUR AU - Foran, J. M. PY - 2010 DA - 2010// TI - New prognostic markers in acute myeloid leukemia: perspective from the clinic JO - Hematol Am Soc Hematol Educ Program VL - 2010 ID - Foran2010 ER - TY - JOUR AU - Prebet, T. AU - Boissel, N. AU - Reutenauer, S. AU - Thomas, X. AU - Delaunay, J. AU - Cahn, J. Y. PY - 2009 DA - 2009// TI - Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.21.0674 DO - 10.1200/JCO.2008.21.0674 ID - Prebet2009 ER -